MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

Soon after the discovery of the Myc gene (c-Myc), it became clear that Myc expression levels
tightly correlate to cell proliferation. The entry in cell cycle of quiescent cells upon Myc …

Promotion of the cell cycle is a major oncogenic mechanism of the oncogene c-MYC (MYC).
MYC promotes the cell cycle by not only activating or inducing cyclins and CDKs but also …

Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive
variants of chronic myeloid leukemia. We provide mechanistic insights into a previously …

In order to facilitate understanding of pigment cell biology, we developed a method to
concomitantly purify melanocytes, iridophores, and retinal pigmented epithelium from …

MYC is a transcription factor that controls the expression of a large fraction of cellular genes
linked to cell cycle progression, metabolism and differentiation. MYC deregulation in tumors …

Occurrence of the BCR-ABLT315I gatekeeper mutation is among the most pressing
challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors …

Chronic myeloid leukemia (CML) is a hematopoietic stem cell (HSC)-driven neoplasia
characterized by expression of the constitutively active tyrosine kinase BCR/Abl. CML …